Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06380205 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06380205 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 24 participants.
The verdict
NCT06380205, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
Interventions
- DRUG Povorcitinib
- DRUG Levonorgestrel/Ethinyl estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2024-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06380205
The ClinicalTrials.gov registry entry for NCT06380205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Povorcitinib is the first listed.
NCT06380205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06380205 about?
NCT06380205 is a clinical study titled "A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females". The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
What is the current status of trial NCT06380205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-05-07. Estimated completion is 2024-06-07.
What interventions are being tested in trial NCT06380205?
The interventions under investigation include: Povorcitinib (DRUG), Levonorgestrel/Ethinyl estradiol (DRUG).
Who is sponsoring clinical trial NCT06380205?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.